|Videos|December 22, 2022

Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

Author(s)Karim Chamie, MD

Karim Chamie, MD, explains how he might approach immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant settings in the future.

Episodes in this series

EP. 1 Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP. 1 Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP. 2 Determining Cisplatin Eligibility for Patients with MIBC

EP. 2 Determining Cisplatin Eligibility for Patients with MIBC

EP. 3 Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP. 3 Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP. 4 Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP. 4 Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP. 5 Case 2 Presentation: A 77-Year-Old Man With MIBC

EP. 5 Case 2 Presentation: A 77-Year-Old Man With MIBC

EP. 6 Unmet Needs and Clinical Challenges in the Management of MIBC

EP. 6 Unmet Needs and Clinical Challenges in the Management of MIBC

EP. 7 Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP. 7 Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP. 8 Clinical Pearls for Community Urologists Treating Patients with MIBC

EP. 8 Clinical Pearls for Community Urologists Treating Patients with MIBC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Alternative BCG strains may help address ongoing supply challenges in NMIBC

ByEugene B. Cone, MD

September 11th 2026

Phase 3 trial of padeliporfin VTP completes treatment in LG-UTUC

ByHannah Clarke

September 10th 2026

John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC

ByJohn P. Sfakianos, MD

September 9th 2026

Dabogratinib shows early activity in FGFR3-altered LG-IR-NMIBC

ByHannah Clarke

September 9th 2026

The critical role of advocacy in urologic oncology

ByRuchika Talwar, MD,Lan Anh Galloway, MD

September 9th 2026

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

AI-generated profiles impersonate female urologists to market ED products online

Alternative BCG strains may help address ongoing supply challenges in NMIBC

Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA

Doublet or triplet? Urologists weighs in on mCSPC options

Prior auth, step therapy, and consolidation pressure: Independent urology's challenge